pantoprazole has been researched along with Infant, Premature, Diseases in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study." | 6.76 | Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. ( Comer, GM; David, ES; Fu, C; Furmaga-Jablonska, W; Kierkus, J; Maguire, MK; Rath, N; Stewart, DL; Sullivan, JE; Wang, W, 2011) |
| "To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study." | 2.76 | Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. ( Comer, GM; David, ES; Fu, C; Furmaga-Jablonska, W; Kierkus, J; Maguire, MK; Rath, N; Stewart, DL; Sullivan, JE; Wang, W, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kierkus, J | 1 |
| Furmaga-Jablonska, W | 1 |
| Sullivan, JE | 1 |
| David, ES | 1 |
| Stewart, DL | 1 |
| Rath, N | 1 |
| Fu, C | 1 |
| Wang, W | 1 |
| Maguire, MK | 1 |
| Comer, GM | 1 |
1 trial available for pantoprazole and Infant, Premature, Diseases
| Article | Year |
|---|---|
Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female | 2011 |